Giredestrant plus Everolimus in Advanced Breast Cancer

NEJM,

10.0 months with giredestrant + everolimus

Median progression-free survival, ESR1-mutated

versus 5.5 months with standard endocrine therapy + everolimus

Take-home

A phase 3 trial evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant significantly improved progression-free survival, particularly in patients with ESR1-mutated tumors: 10.0 versus 5.5 months.

Benefits were also observed across the overall population, while adverse-event rates were broadly similar between treatment groups.

Read the paper in NEJM

More on breast cancer